Harpel P C, Lewin M F, Kaplan A P
J Biol Chem. 1985 Apr 10;260(7):4257-63.
We have previously described an enzyme-linked immunosorbent assay for the quantification of C-1 inactivator-kallikrein complexes in plasma (Lewin, M. F., Kaplan, A. P., and Harpel, P. C. (1983) J. Biol. Chem. 258, 6415-6421). We have now developed an immunoimmobilization-enzyme assay for alpha 2-macroglobulin-kallikrein complexes. In this assay these complexes are removed from plasma by immunoabsorption with the IgG fraction of rabbit anti-alpha 2-macroglobulin antiserum coupled to an agarose gel. The immobilized alpha 2-macroglobulin-kallikrein complex hydrolyzes the fluorogenic substrate D-Ser-Pro-Phe-Arg-7-amino-4-trifluoromethyl coumarin, and this activity is proportional to the concentration of complexes in the plasma. Using these assays we have studied the distribution of plasma kallikrein between its inhibitors under several different experimental conditions. When kallikrein is added to plasma, about 57% binds to C-1 inactivator and 43% to alpha 2-macroglobulin. When prekallikrein is activated endogenously in plasma by the addition of kaolin or Hageman factor fragment, approximately 84% of kallikrein is now bound to C-1 inactivator and 16% to alpha 2-macroglobulin. Temperature dramatically affects the distribution of kallikrein. The binding of kallikrein to alpha 2-macroglobulin in plasma is inversely related to temperature, whereas the binding to C-1 inactivator is directly related: 85% of the kallikrein is bound to alpha 2-macroglobulin at 4 degrees C, whereas at 37 degrees C, only 33% is bound. The total amount of kallikrein bound to the two inhibitors is similar at each temperature. These studies thus provide new insight concerning kallikrein formation and regulation in plasma.
我们之前描述了一种用于定量血浆中C-1灭活剂-激肽释放酶复合物的酶联免疫吸附测定法(Lewin, M. F., Kaplan, A. P., and Harpel, P. C. (1983) J. Biol. Chem. 258, 6415 - 6421)。我们现在开发了一种用于α2-巨球蛋白-激肽释放酶复合物的免疫固定化酶测定法。在该测定法中,这些复合物通过与琼脂糖凝胶偶联的兔抗α2-巨球蛋白抗血清的IgG部分进行免疫吸附从血浆中去除。固定化的α2-巨球蛋白-激肽释放酶复合物水解荧光底物D-丝氨酸-脯氨酸-苯丙氨酸-精氨酸-7-氨基-4-三氟甲基香豆素,并且这种活性与血浆中复合物的浓度成正比。使用这些测定法,我们研究了在几种不同实验条件下血浆激肽释放酶在其抑制剂之间的分布。当将激肽释放酶添加到血浆中时,约57%与C-1灭活剂结合,43%与α2-巨球蛋白结合。当通过添加高岭土或Hageman因子片段在血浆中内源性激活前激肽释放酶时,现在约84%的激肽释放酶与C-1灭活剂结合,16%与α2-巨球蛋白结合。温度显著影响激肽释放酶的分布。血浆中激肽释放酶与α2-巨球蛋白的结合与温度呈负相关,而与C-1灭活剂的结合呈正相关:在4℃时,85%的激肽释放酶与α2-巨球蛋白结合,而在37℃时,仅33%结合。在每个温度下,与两种抑制剂结合的激肽释放酶总量相似。因此,这些研究为血浆中激肽释放酶的形成和调节提供了新的见解。